Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention

Current Medical Research and Opinion

Volumn 31, Issue 2, 2015, Pages 191-195

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic kidney disease; Clinical events; Contrast induced nephropathy; High intensity statin treatment; Percutaneous coronary intervention; Survival

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CREATINE KINASE MB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGLOBIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; TROPONIN I; UNCLASSIFIED DRUG; CONTRAST MEDIUM;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; DRUG MEGADOSE; EVENT FREE SURVIVAL; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART INJURY; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HIGH RISK PATIENT; HUMAN; INFLAMMATION; KIDNEY FUNCTION; LONG TERM CARE; MORBIDITY; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PROSPECTIVE STUDY; RENAL PROTECTION; REVIEW; RISK REDUCTION; SHORT COURSE THERAPY; STABLE ANGINA PECTORIS; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; CHEMOPROPHYLAXIS; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; PERIOPERATIVE PERIOD; PROCEDURES;

AGED; CHEMOPREVENTION; CONTRAST MEDIA; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD;

EID: 84923384596     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.954666     Document Type: Review

References (33)

1. Tentzeris I, Rohla M, Jarai R, et al. Influence of high-dose highly efficient statins on short-term mortality in patients undergoing percutaneous coronary intervention with stenting for acute coronary syndromes. Am J Cardiol 2014;113:1099-104
2. Navarese EP, Kowalewski M, Andreotti F, et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2014;113:1753-64
3. Kasai T, Miyauchi K, Kurata T, et al. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 2007;114:210-17
4. Athyros VG, Tziomalos K, Florentin M, et al. Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect? Curr Med Res Opin 2010;26:839-42
5. Kaneko H, Yajima J, Oikawa Y, et al. Recent characteristics and outcomes of Japanese stable angina pectoris after percutaneous coronary intervention. An observational cohort study using the Shinken Database. Int Heart J 2013;54:335-40
6. Pasceri V, Patti G, Nusca A, et al; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2004;110:674-8
7. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007;49:1272-8
8. Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006;48:1560-6
9. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54:558-65
10. Ray KK, Cannon CP, Mccabe CH, et al; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405-10
11. Gibson CM, Pride YB, Hochberg CP, et al; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009;54:2290-5
12. de Lemos JA, Blazing MA, Wiviott SD, et al; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
13. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004;292:1365-7
14. Li XD, Yang YJ, Hao YC, et al. Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a metaanalysis. Chin Med J (Engl) 2013;126:1755-60
15. Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short and long-term implications. Semin Nephrol 2011;31:300-9
16. Hoshi T, Sato A, Kakefuda Y, et al. Preventive effect of statin pretreatment on contrast-induced acute kidney injury in patients undergoing coronary angioplasty: propensity score analysis from a multicenter registry. Int J Cardiol 2014;171:243-9
17. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrastinduced nephropathy prevention in acute coronary syndrome. Results from the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome). J Am Coll Cardiol 2014;63:71-9
18. Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014;63:62-70
19. Mikhailidis DP, Athyros VG. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol 2014;10:8-9
20. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012;126:3008-16
21. Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial). Am J Cardiol 2011;108:1-7
22. Dormuth CR, Hemmelgarn BR, Paterson JM, et al; Canadian Network for Observational Drug Effect Studies. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880
23. Sarma A, Cannon CP, de Lemos J, et al. The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. J Am Heart Assoc 2014;3:e000784
24. Bangalore S, Fayyad R, Hovingh GK, et al; Treating to New Targets Steering Committee and Investigators. Statin and the risk of renal-related serious adverse events: analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol 2014;113:2018-20
25. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
26. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-9
27. Shepherd J, Kastelein JJ, Bittner V, et al; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-54
28. Athyros VG, Karagiannis A, Katsiki N, Mikhailidis DP. Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. Am J Cardiol 2012;110:763
29. Kaneko H, Yajima J, Oikawa Y, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 2014;29:21-8
30. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-85
31. Komatsu T, Tachibana H, Sato Y, et al. Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. Int Heart J 2011;52:359-65
32. Saab FA, Eagle KA, Kline-Rogers E, et al; on behalf of the Michigan Cardiovascular Outcomes Research and Reporting Program [MCORRP] of the University of Michigan Cardiovascular Center. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. Am J Cardiol 2004;94:1166-8
33. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? Curr Med Res Opin 2008;24:3059-62